| (CCTG) IND.238 | A Phase II Study of Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity | Dr Peter Ellis | Suspended/On hold | NCT03847649 |
| (Bold Therapeutics) BOLD-100-001 / TRIO039 | A Phase 1b Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours | Dr Elaine McWhirter | Open to recruitment | NCT04421820 |
| (BMS) CA052-002 | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors | Dr Sebastien Hotte | Suspended/On hold | NCT04895709 |
| (Conjupro) CPO301-US-101 | A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors. | Dr Rosalyn Juergens | Suspended/On hold | NCT05948865 |
| (Merck) MK-1084-001 | A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors | Dr Rosalyn Juergens | Open to recruitment | NCT05067283 |
Find a Trial
Contact Us